Evidence map›Paper›PMID 27148368›Full record

ArticleStem cells international2016

Genome Editing of the CYP1A1 Locus in iPSCs as a Platform to Map AHR Expression throughout Human Development.

Brenden W Smith, Elizabeth A Stanford, David H Sherr, George J Murphy

Open access · goldAbstract read
In one paragraph

Article in Stem cells international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Brenden W SmithSection of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA; Center for Regenerative Medicine (CReM), Boston University and Boston Medical Center, Boston, MA 02118, USA.
Elizabeth A StanfordSection of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA; Center for Regenerative Medicine (CReM), Boston University and Boston Medical Center, Boston, MA 02118, USA; Department of Environmental Health, Boston University School of Public Health, Boston, MA 02118, USA.
David H SherrDepartment of Environmental Health, Boston University School of Public Health, Boston, MA 02118, USA.
George J MurphySection of Hematology and Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA 02118, USA; Center for Regenerative Medicine (CReM), Boston University and Boston Medical Center, Boston, MA 02118, USA.
Boston Medical Center · USBoston University · US

Funding

Training CoreP42ES007381 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI SHERR, DAVID H · 1995 to 2019
$46.1M
Signaling Pathways in Stages of TumorigenesisP01ES011624 · NIEHS · TUFTS UNIVERSITY BOSTON · PI SONENSHEIN, GAIL E. · 2001 to 2012
$11.4M
Globin Gene Expression in Sickle Cell Genotype-Specific iPS cellsU01HL107443 · NHLBI · BOSTON UNIVERSITY MEDICAL CAMPUS · PI CHUI, DAVID H K, MOSTOSLAVSKY, GUSTAVO · 2011 to 2015
$8.3M
Defining the Role of the AHR in Blood Cell SpecificationsR01ES025409 · NIEHS · BOSTON UNIVERSITY MEDICAL CAMPUS · PI MURPHY, GEORGE J, SHERR, DAVID H · 2016 to 2020
$1.8M
NHLBI NIH HHS U01 HL107443NIEHS NIH HHS P01 ES011624NIEHS NIH HHS P42 ES007381NIEHS NIH HHS R01 ES025409
6 · The paper itself

Abstract

The aryl hydrocarbon receptor (AHR) is a ligand activated transcription factor that increases the expression of detoxifying enzymes upon ligand stimulation. Recent studies now suggest that novel endogenous roles of the AHR exist throughout development. In an effort to create an optimized model system for the study of AHR signaling in several cellular lineages, we have employed a CRISPR/CAS9 genome editing strategy in induced pluripotent stem cells (iPSCs) to incorporate a reporter cassette at the transcription start site of one of its canonical targets, cytochrome P450 1A1 (CYP1A1). This cell line faithfully reports on CYP1A1 expression, with luciferase levels as its functional readout, when treated with an endogenous AHR ligand (FICZ) at escalating doses. iPSC-derived fibroblast-like cells respond to acute exposure to environmental and endogenous AHR ligands, and iPSC-derived hepatocytes increase CYP1A1 in a similar manner to primary hepatocytes. This cell line is an important innovation that can be used to map AHR activity in discrete cellular subsets throughout developmental ontogeny. As further endogenous ligands are proposed, this line can be used to screen for safety and efficacy and can report on the ability of small molecules to regulate critical cellular processes by modulating the activity of the AHR.

Identifiers

PMID27148368
PMCPMC4842384
OpenAlexW2322589772

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.